New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

KARDIGAN INC (KARD) Return on invested capital

Alert me on Return on invested capital

KARDIGAN INC's return on invested capital over the twelve months to Sep 30, 2026 was −187.2%, down 187.2 percentage points from fiscal 2025 (0.00%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Return on invested capital, annual

Embed this chart

Annual newest first

Period Return on invested capital Change (points)
FY2025 0.00% 0.00
FY2024 0.00% —

Return on invested capital against peers

What Return on invested capital is

Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.

TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)

The full definition of Return on invested capital →

More on KARD